Eisai Co. (4523.T, EII.SG) and Biogen (BIIB) announced that once weekly lecanemab-irmb subcutaneous injection - LEQEMBI IQLIK - is now available in the U.S. for initiation therapy for early Alzheimer's disease in adults with mild cognitive impairment or mild dementia due to AD, collectively referred...
Shares of Arbutus Biopharma Corporation (ABUS) are gaining about 11 percent on Friday morning after the company announced its plan to repurchase up to $230 million of its common shares through a modified Dutch Auction tender offer, returning proceeds from its recent settlement with Moderna to shareholders. The...
3S Bio (SSRX, 01530.HK) Friday announced 26.5 percent increase in first half net earnings attributable to equity holders, while revenues were up 3.9 percent from the prior year. In its interim results for the first half the company reported Net profit attributable to equity holders of RMB 1.15 billion....
Shares of Brii Biosciences Limited (2137.HK) gained around 5% on the Hong Kong stock exchange, after the company reported Friday a narrower loss in its first half. Loss for the period attributable to owners of the company was RMB100.56 million, compared to loss of RMB148.067 million last year. Loss...
On Monday, InnoCare Pharma Limited (9969.HK) reported a return to profit in the first half of 2026, compared to a loss in the same half in the previous year, due to higher revenue generated. Profit attributable to the owners of the parent was RMB 246.36 million or RMB 0.14 per share, compared with...
Gilead Sciences (GILD) announced the European Commission has granted marketing authorization for Trodelvy in combination with Keytruda for the treatment of adult patients with unresectable, locally advanced or metastatic triple-negative breast cancer who have not received prior systemic therapy for...
Get our FREE PDF — "The Next 30 Days Of FDA Events" — featuring upcoming PDUFA Dates and FDA Advisory Panel Reviews. No subscription required.
EyePoint, Inc. (EYPT), a clinical-stage biopharmaceutical company, on Monday reported topline results from the Phase 3 LUGANO trial, evaluating Duravyu, an investigational sustained-delivery treatment for wet age-related macular degeneration (wet AMD). The trial did not achieve its primary endpoint...
British drug major AstraZeneca Plc (AZN, AZN.L) announced Monday positive results from SAFFRON Phase III trial, with Tagrisso (osimertinib) plus Orpathys (savolitinib) demonstrating statistically significant and clinically meaningful improvements in epidermal growth factor receptor-mutated or EGFRm lung...
argenx SE (ARGX), an immunology company, on Monday announced positive topline results from the Phase 3 ALKIVIA study evaluating VYVGART Hytrulo in adults with autoimmune myositis. The study met its primary endpoint, with patients treated with VYVGART Hytrulo demonstrating a statistically significant...
Neurocrine Biosciences, Inc. (NBIX) on Wednesday announced the publication of findings from its Phase 4 KINECT-PRO study in CNS Spectrums, showing that once-daily Ingrezza improved patient-reported quality of life and daily functioning in people living with tardive dyskinesia (TD). The study also...
United Therapeutics Corp. (UTHR), a public benefit corporation, announced Monday that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for ralinepag to treat pulmonary arterial hypertension or PAH. The FDA has set a Prescription Drug User Fee Act target action...
The August FDA calendar spans a wide range of indications - from the ultra-rare Fibrodysplasia Ossificans Progressiva (FOP) to melanoma, Alzheimer's disease, multiple myeloma, Duchenne muscular dystrophy (DMD), Glycogen Storage Disease, HIV, and essential thrombocythemia.
August 13, 2026 05:33 ET The World Health Organization’s cancer research agency, the International Agency for Research on Cancer (IARC), has classified three widely used medicines as carcinogenic to humans.
Longeveron Inc. (LGVN), a clinical-stage biotechnology company developing cellular therapy, announced a 1-for-10 reverse split of the company's Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share. The reverse stock split is intended to help the company...
A large study of adults in the U.S. suggests that when you eat your first and last calories of the day may be linked to how long you live. For the study, researchers looked at health and diet information from 31,044 adults aged 40 and older, collected between 1999 and 2018. Participants reported everything...
A new study published in Memory & Cognition suggests that taking screenshots may actually make it harder to remember what we see. The study involved 892 undergraduate students aged 17 to 27 at Binghamton University. In most experiments, students used their own smartphones to look at artwork. They...
Eating lunch between 12 p.m. and 2 p.m. may help support energy levels, blood sugar control and overall metabolic health, according to research summarised by Health. However, consistency in meal timing may matter more than adhering to an exact lunchtime.
The Democratic Republic of the Congo (DRC) is set to receive 70,000 doses of the Ervebo Ebola vaccine as the country continues to deal with its largest Ebola outbreak, the World Health Organization (WHO) said on Thursday. This comes after Congolese government requested the release of Ervebo vaccines...
Legend Biotech Corporation (LEGN), a clinical-stage biopharmaceutical company, announced Monday that its Board of Directors had appointed Alan Bash as the interim Chief Executive Officer (CEO) after Ying Huang stepped down from the role on July 24, 2026. Huang joined Legend Biotech in July 2019 and...